Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Vical receives orphan drug status for Allovectin-7

Oct. 28, 1999

StessGen begins trial of HspE7 for anal dysplasia

Oct. 27, 1999

Development of OvaRex is now sole focus for AltaRex

Oct. 26, 1999

Human trials initiated for IL-13 cytotoxin under development by NeoPharm

Oct. 20, 1999

AltaRex reports new partnering plans for OvaRex MAb

Oct. 19, 1999

ImmunoGen presents positive pharmacokinetic data for huC242-DM1/SB-408075

Oct. 19, 1999

Neurocrine Biosciences' NBI-3001 granted fast track designation

Oct. 18, 1999

Immune Response reports data from phase I colon cancer vaccine study

Oct. 18, 1999

Endorex study shows immune response stimulation by ImmTher in human cancer cells

Oct. 18, 1999

Antimetastatic activity demonstrated for new MAb in breast cancer-bearing mice

Oct. 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...